By PPN News Staff
The FDA expanded the approved use of mepolizumab (Nucala, GlaxoSmithKline) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis. This new indication provides the first FDA-approved therapy specifically to treat EGPA.
EGPA (formerly known as Churg-Strauss syndrome) is a condition characterized by asthma, high levels of eosinophils and inflammation of small- to medium-sized blood vessels. The inflamed